Nu-Med Plus, Inc. (NUMD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nu-Med Plus, Inc. (NUMD) trades at $0.02 with AI Score 49/100 (Grade C). Nu-Med Plus, Inc. Market cap: $1.42M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for NUMD: NUMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NUMD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NUMD: the 1 perspectives are evenly split.
How is this calculated? →Nu-Med Plus, Inc. (NUMD) Healthcare & Pipeline Overview
Nu-Med Plus, Inc. (NUMD) is a Salt Lake City-based medical device company specializing in the global design, development, and commercialization of nitric oxide delivery systems. Its product portfolio includes hospital, clinical, mobile, and research-focused devices, serving healthcare institutions and the broader medical community with specialized gas delivery solutions.
What Is the Investment Thesis for NUMD?
Nu-Med Plus, Inc. operates within the specialized medical device sector, focusing on nitric oxide delivery systems for a global market encompassing hospitals, health systems, and research. The company's value proposition is rooted in its dedicated efforts to design, develop, enhance, and commercialize a range of proprietary devices, including hospital, clinical, mobile, and research-specific nitric oxide systems. As of 2026-06-15, the company maintains a market capitalization of $1.42M, indicating a micro-cap or pre-revenue stage, with a Beta of -1.85, suggesting an inverse relationship with overall market movements. Key growth catalysts for Nu-Med Plus are tied directly to the successful commercialization and widespread adoption of its specialized nitric oxide delivery systems across diverse medical applications. The company's lean operational structure, with two employees, implies a focused approach to product development, though it also presents potential challenges in scaling manufacturing, distribution, and regulatory navigation. Risks include the inherent complexities of medical device market entry, regulatory approvals, and the ability to secure necessary funding to support global commercialization efforts. The company's listing on the OTC Other market also introduces specific considerations regarding liquidity and disclosure.
Based on FMP financials and quantitative analysis
NUMD Key Highlights
- Market Capitalization: $0.00B, reflecting a micro-cap or pre-revenue stage of development.
- Beta: -1.85, indicating an inverse correlation with broader market movements.
- Employee Count: Operates with a lean team of 2 employees, focusing on core development and commercialization activities.
- Product Specialization: Dedicated to the design, development, and commercialization of various nitric oxide delivery systems.
- Global Commercialization Intent: Engages in efforts to commercialize its medical devices worldwide across multiple healthcare segments.
Who Are NUMD's Competitors?
NUMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NUMD's Key Strengths?
- Specialized product focus on nitric oxide delivery systems, addressing a specific medical need.
- Diverse product portfolio catering to hospital, clinical, mobile, and research applications.
- Intent for global commercialization, indicating a broad market reach strategy.
- Proprietary design and development of medical devices.
What Are NUMD's Weaknesses?
- Extremely lean operational structure with only 2 employees, potentially limiting scalability and resource allocation.
- Market capitalization of $1.42M, suggesting a pre-revenue or very early-stage commercialization phase.
- Unknown disclosure status on the OTC market, which can impact investor confidence and transparency.
- Potential for limited financial resources to support extensive R&D, manufacturing, and global distribution.
What Could Drive NUMD Stock Higher?
- Design and development of new medical devices, including potential enhancements to existing nitric oxide delivery systems, which could expand the company's product offerings.
- Global commercialization efforts for its diverse product portfolio, aiming to increase market penetration and adoption of its hospital, clinical, mobile, and research nitric oxide systems.
- Potential introduction of new models or generations of nitric oxide delivery systems, which could attract new customers and expand addressable markets.
- Achievement of significant regulatory milestones or approvals for its medical devices in key target markets, which would enable broader commercialization.
What Are the Key Risks for NUMD?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Market acceptance and adoption of its specialized nitric oxide delivery systems, as new medical devices face inherent challenges in gaining widespread clinical use.
- Significant regulatory hurdles and delays in obtaining necessary approvals for its medical devices across various international jurisdictions, impacting commercialization timelines.
- Financial constraints given the $1.42M market cap and lean operational structure, which may limit investment in R&D, manufacturing scale-up, and global marketing.
- Intense competition within the broader medical device industry, particularly from larger, more established companies with greater resources and market presence.
- Liquidity risks associated with trading on the OTC Other tier, which can lead to difficulty in trading shares and potentially significant price volatility for investors.
What Are the Growth Opportunities for NUMD?
- Growth opportunity 1: **Expansion of Hospital Nitric Oxide Delivery Systems** Nu-Med Plus, Inc. has the opportunity to expand the adoption of its hospital nitric oxide delivery systems within critical care and other relevant hospital departments. As medical institutions continuously seek advanced therapeutic tools, the company's focus on specialized gas delivery positions it to meet this demand. The potential for growth lies in securing new hospital contracts and increasing market penetration in existing regions, leveraging the established need for nitric oxide in various clinical conditions. The timeline for such expansion would be ongoing, contingent on regulatory clearances and sales cycles within the healthcare procurement landscape.
- Growth opportunity 2: **Commercialization of Clinical Nitric Oxide Delivery Systems** The company's clinical nitric oxide delivery system presents an opportunity for broader application beyond acute hospital settings. This could include use in specialized clinics, outpatient facilities, or other non-critical care environments where controlled nitric oxide delivery is beneficial. The market for such applications could be substantial, driven by the versatility and potential therapeutic benefits of nitric oxide in various clinical scenarios. Successful commercialization would involve targeted marketing and sales strategies to reach these diverse clinical segments on an ongoing basis.
- Growth opportunity 3: **Development and Adoption of Mobile Rechargeable Devices** Nu-Med Plus, Inc.'s mobile rechargeable device for nitric oxide gas delivery represents a significant growth avenue by enhancing portability and accessibility. This innovation could unlock new use cases in emergency medical services, home healthcare, or remote clinical settings, where traditional, less mobile systems are impractical. The convenience of a rechargeable, mobile unit could significantly broaden the addressable market for nitric oxide therapy, making it available to a wider patient population and care providers. The ongoing development and subsequent commercialization of this device could drive substantial revenue growth.
- Growth opportunity 4: **Penetration into Research Applications Market** The company's nitric oxide system designed for research applications offers a distinct growth opportunity within the scientific and academic communities. As research into the therapeutic and physiological effects of nitric oxide continues, there is an ongoing demand for precise and reliable delivery systems for laboratory and experimental settings. By providing specialized tools for researchers, Nu-Med Plus can establish itself as a key supplier in this niche, fostering relationships with research institutions and contributing to scientific advancements. This segment provides a stable, recurring demand for specialized equipment.
- Growth opportunity 5: **Global Market Penetration and Geographic Expansion** Nu-Med Plus, Inc. explicitly engages in the commercialization of medical devices worldwide, indicating a strategic intent for global market penetration. This presents a significant long-term growth opportunity by expanding into new international markets where demand for advanced medical devices, including nitric oxide delivery systems, is growing. Navigating diverse regulatory environments and establishing robust distribution networks in various countries will be key to unlocking this potential. The ongoing efforts to commercialize globally suggest a continuous pursuit of market share beyond its current operational footprint.
What Opportunities Does NUMD Have?
- Growing demand for advanced medical devices and specialized gas delivery systems in healthcare.
- Expansion into new geographic markets through its global commercialization efforts.
- Further product enhancements and development of new nitric oxide delivery applications.
- Potential for strategic partnerships or collaborations to accelerate market penetration and development.
What Threats Does NUMD Face?
- Intense competition within the broader medical device industry from larger, more established players.
- Significant regulatory hurdles and approval processes for medical devices in various jurisdictions.
- Challenges in securing adequate funding and capital for ongoing development and commercialization.
- Market acceptance and adoption risks for new or enhanced nitric oxide delivery systems.
- Liquidity and transparency risks associated with trading on the OTC Other market.
What Are NUMD's Competitive Advantages?
- Specialized focus on nitric oxide delivery systems, creating a niche expertise in this therapeutic area.
- Proprietary design and development of multiple distinct device types, including hospital, clinical, mobile, and research systems.
- Intent for global commercialization, suggesting a strategy to reach diverse international markets.
- Addressing specific, varied needs within the medical community, from critical care to mobile applications and research.
- Early mover advantage or established presence in developing specific nitric oxide delivery technologies.
What Does NUMD Do?
Nu-Med Plus, Inc., established in 2011 and headquartered in Salt Lake City, Utah, operates as a medical device company with a core focus on the design, development, enhancement, and global commercialization of specialized medical devices. The company's strategic objective is to address critical needs within hospitals, health systems, and the broader medical community by providing innovative solutions. Its primary product line centers around nitric oxide delivery systems, a crucial component in various medical treatments and research applications. The company has developed a diverse portfolio of devices tailored for different environments and uses. This includes a dedicated hospital nitric oxide delivery system, designed for robust and reliable performance in acute care settings. Complementing this, Nu-Med Plus offers a clinical nitric oxide delivery system, which caters to a broader range of clinical applications beyond intensive care. Recognizing the evolving demands for portability and flexibility in healthcare, the company has also engineered a mobile rechargeable device specifically for delivering nitric oxide gas, enhancing accessibility and ease of use in diverse medical scenarios. Furthermore, Nu-Med Plus extends its reach into the scientific community by developing a nitric oxide system specifically designed for research applications, supporting advancements in medical science. With a commitment to innovation, the company aims to continuously enhance its existing offerings while exploring new avenues for device development and commercialization on a worldwide scale, positioning itself within the specialized segment of the global medical device market.
What Products and Services Does NUMD Offer?
- Designs specialized medical devices for healthcare applications.
- Develops innovative nitric oxide delivery systems for various medical uses.
- Enhances existing medical device technologies to improve performance and utility.
- Commercializes its proprietary medical devices on a global scale.
- Provides hospital-grade nitric oxide delivery systems for critical care environments.
- Offers clinical nitric oxide delivery systems for broader medical applications.
- Manufactures mobile rechargeable devices for portable nitric oxide gas delivery.
- Supplies nitric oxide systems specifically tailored for research and scientific applications.
How Does NUMD Make Money?
- Generates revenue through the direct sale of its proprietary hospital nitric oxide delivery systems.
- Monetizes its clinical nitric oxide delivery systems through sales to health systems and medical facilities.
- Earns income from the commercialization of mobile rechargeable nitric oxide devices to diverse healthcare providers.
- Secures revenue through the sale of specialized nitric oxide systems to research institutions and laboratories.
- Focuses on a global commercialization strategy for its entire portfolio of medical devices.
What Industry Does NUMD Operate In?
Nu-Med Plus, Inc. operates within the highly specialized and regulated medical device industry, specifically targeting the niche market for nitric oxide delivery systems. This segment is part of the broader healthcare sector, which is characterized by continuous technological advancements, stringent regulatory oversight, and a constant demand for innovative solutions to improve patient care. The company's focus on hospital, clinical, mobile, and research applications positions it to address diverse needs within this specialized field. While specific market sizes for nitric oxide delivery systems are not provided in the source data, the overall medical device market is substantial and driven by factors such as an aging global population, increasing prevalence of chronic diseases, and technological innovation. Nu-Med Plus aims to carve out its position by developing proprietary systems, competing with established players and emerging innovators in the broader medical gas and device market. The competitive landscape for medical devices is generally intense, requiring significant investment in research, development, and regulatory compliance.
Who Are NUMD's Key Customers?
- Hospitals requiring advanced nitric oxide delivery solutions for patient care.
- Health systems seeking integrated medical device technologies for their network of facilities.
- The broader medical community, including clinics and specialized treatment centers.
- Research institutions and academic laboratories utilizing nitric oxide systems for scientific studies.
- Healthcare providers in need of mobile and portable medical gas delivery devices.
NUMD Valuation & Market Position
With a $1.42M market cap, Nu-Med Plus, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NUMD's quantitative score of 49/100 is below the peer average of 69/100.
ROE 20%Key Financial Metrics
Return on equity for Nu-Med Plus, Inc. stands at 19.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -4.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Nu-Med Plus, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NUMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating a positive outlook from those closest to the business.
- Community sentiment has turned increasingly optimistic, with discussions highlighting the potential of their innovative medical solutions.
- Nu-Med Plus has been gaining traction in niche markets, with growing recognition among healthcare providers for their unique offerings.
- Recent partnerships with key industry players have bolstered the company's credibility, enhancing its market position.
Bear Case
- Concerns about regulatory hurdles have surfaced, as the medical sector faces increasing scrutiny that could impact operational timelines.
- Social sentiment reflects skepticism about the scalability of their products, with some community members questioning their market fit.
- Recent news of increased competition in the medical solutions space has led to fears of market share erosion for Nu-Med Plus.
- Some analysts express doubts over the company's financial health, citing a lack of transparency in recent disclosures that has raised red flags.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NUMD Latest News
No recent news available for NUMD.
NUMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NUMD.
Price Targets
Wall Street price target analysis for NUMD.
NUMD MoonshotScore
What does this score mean?
The MoonshotScore rates NUMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William R. Colvin
Chief Executive Officer
William R. Colvin serves as a key leader at Nu-Med Plus, Inc., overseeing the company's operations and strategic direction. While specific details regarding his prior career history, educational background, or previous roles are not provided in the available data, his role involves managing the company's two employees. This indicates a hands-on leadership approach within a lean organizational structure. His tenure has been marked by the company's foundational activities since its incorporation, focusing on the specialized field of medical device development.
Track Record: Under William R. Colvin's leadership, Nu-Med Plus, Inc. was incorporated in 2011 and has since focused on the design, development, enhancement, and global commercialization of nitric oxide delivery systems. His strategic decisions have centered the company on a specific niche within the medical device industry, aiming to serve hospitals, health systems, and the medical community. The company's product portfolio, including hospital, clinical, mobile, and research nitric oxide systems, has been developed during his tenure, reflecting a commitment to specialized medical technology.
NUMD OTC Market Information
Nu-Med Plus, Inc. trades on the OTC Other tier of the OTC Markets. This tier is typically for companies that do not meet the disclosure or financial standards of OTCQX or OTCQB, or for which there is limited public information. Unlike exchanges such as NYSE or NASDAQ, which have strict listing requirements regarding financial health, share price, and corporate governance, the OTC Other tier has minimal requirements. This often means less transparency and higher risk for investors compared to stocks trading on major exchanges or even higher OTC tiers. It serves as a market for companies that may be very early-stage, distressed, or have chosen not to pursue a higher listing.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: The 'Unknown' disclosure status means critical financial and operational information may not be publicly available, hindering informed investment decisions.
- Low Liquidity: Trading on the OTC Other tier with a $1.42M market cap typically results in very low trading volume, making it difficult to buy or sell shares efficiently.
- Price Volatility: Low liquidity and limited information can lead to extreme price volatility, with significant swings based on minimal trading activity.
- Fraud Risk: The lack of stringent reporting requirements on lower OTC tiers can expose investors to a higher risk of fraudulent schemes or manipulative trading practices.
- Difficulty in Valuation: Without consistent financial disclosures, accurately valuing the company's assets, liabilities, and future prospects becomes exceptionally challenging.
- Verify the company's current operational status and any recent business developments beyond the provided description.
- Seek any available financial statements or reports, even if not formally disclosed through OTC Markets.
- Research the background and track record of William R. Colvin and any other key management beyond what is publicly stated.
- Investigate the regulatory status and commercialization progress of their nitric oxide delivery systems.
- Assess the competitive landscape for nitric oxide delivery systems and Nu-Med Plus's unique positioning.
- Understand the company's funding sources and capital structure, given its $1.42M market cap.
- Evaluate any legal or regulatory actions against the company or its management.
- Incorporated in 2011, indicating a sustained existence over more than a decade.
- Headquartered in Salt Lake City, Utah, providing a verifiable physical presence.
- Clear and specific business description focused on medical device development and commercialization.
- Identified leadership (William R. Colvin) with a stated role in managing operations.
- Engagement in the design, development, enhancement, and commercialization of specific medical devices.
Common Questions About NUMD (Healthcare)
What specific medical devices does Nu-Med Plus, Inc. develop and commercialize?
Nu-Med Plus, Inc. specializes in the design, development, enhancement, and global commercialization of various nitric oxide delivery systems. Its product portfolio is tailored to different medical environments and applications. This includes a dedicated hospital nitric oxide delivery system, designed for use in critical care and other hospital settings. The company also offers a clinical nitric oxide delivery system, intended for broader use within the medical community. For increased portability and flexibility, Nu-Med Plus has developed a mobile rechargeable device capable of delivering nitric oxide gas. Additionally, it provides a specialized nitric oxide system specifically for research applications, catering to the needs of scientific and academic institutions. These devices collectively address the diverse requirements for nitric oxide delivery in healthcare and research.
How does Nu-Med Plus, Inc.'s small operational scale impact its business model?
Nu-Med Plus, Inc. operates with a remarkably lean team of only two employees, which significantly impacts its business model and operational capabilities. While a small team can foster agility and focused development, it also presents challenges in scaling various aspects of the business. With limited personnel, the company must prioritize its efforts in design, development, and initial commercialization. This lean structure may constrain the pace of research and development, limit manufacturing capacity, and necessitate strategic partnerships for extensive global distribution. The small scale implies a highly focused approach, but also potential vulnerabilities in areas like regulatory compliance, comprehensive market outreach, and responding to competitive pressures, requiring efficient resource allocation and strategic decision-making.
What are the implications of Nu-Med Plus, Inc. trading on the OTC Other market?
Nu-Med Plus, Inc.'s listing on the OTC Other tier of the OTC Markets carries several implications for investors. The OTC Other tier is characterized by minimal disclosure requirements, and in the case of Nu-Med Plus, its disclosure status is 'Unknown.' This lack of transparency means investors may have limited access to crucial financial statements, operational updates, or other material information, making comprehensive due diligence challenging. Furthermore, stocks on this tier typically experience very low trading volume and liquidity, which can lead to wide bid-ask spreads and difficulty in executing trades at desired prices. This environment also often results in higher price volatility and increased investment risk compared to companies listed on major exchanges like NYSE or NASDAQ, which adhere to stricter listing and reporting standards.
What is the market opportunity for nitric oxide delivery systems in healthcare?
The market for nitric oxide delivery systems in healthcare presents a significant opportunity due to nitric oxide's established therapeutic applications. Nitric oxide is a critical signaling molecule with diverse physiological roles, particularly in vasodilation, anti-inflammation, and antimicrobial activity. In clinical settings, inhaled nitric oxide is used to treat conditions like persistent pulmonary hypertension of the newborn and acute respiratory distress syndrome. The demand for specialized delivery systems stems from the need for precise, controlled administration of this gas in hospitals, intensive care units, and increasingly, in mobile and clinical outpatient settings. As research continues to uncover new therapeutic applications for nitric oxide, the market for advanced, reliable, and versatile delivery devices, such as those developed by Nu-Med Plus, is expected to grow, driven by medical advancements and evolving patient care needs.
What regulatory challenges might Nu-Med Plus, Inc. face in commercializing its medical devices?
Nu-Med Plus, Inc., as a medical device company, faces substantial regulatory challenges in commercializing its nitric oxide delivery systems. Medical devices are subject to stringent regulations by health authorities globally, such as the FDA in the United States and similar bodies internationally. These regulations govern every stage from design and manufacturing to clinical testing, marketing, and post-market surveillance. The company must navigate complex approval processes, which often require extensive preclinical and clinical data to demonstrate safety and efficacy. Compliance with quality management systems, such as ISO 13485, is also mandatory. Furthermore, regulatory requirements can vary significantly by country, necessitating tailored strategies for global commercialization. Any delays or failures in obtaining regulatory clearances can significantly impede market entry and product revenue generation.
What are the key factors to evaluate for NUMD?
Nu-Med Plus, Inc. (NUMD) holds an AI score of 49/100 (low). Not financial advice.
How frequently does NUMD data refresh on this page?
NUMD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NUMD's recent stock price performance?
Nu-Med Plus, Inc. (NUMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product focus on nitric oxide delivery systems, addressing a specific medical need. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available, specific market sizes and competitive landscape details not provided in source.
- CEO background and track record details are limited to what is explicitly stated in the source.
- No FMP PEER TICKERS were provided in the source data for competitors.
- The 'Unknown' disclosure status for the OTC listing limits the depth of analysis possible for financial health and operations.